NEURELIS ANNOUNCES FILING OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Neurelis, Inc., announced the company will present nine posters at the 76th American Epilepsy Society Annual Meeting (AES), December 2 – 6,.
NEURELIS TO PRESENT NINE POSTERS AT THE 76TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Tris Pharma, Inc. ("Tris"), an innovative and fully integrated pharmaceutical company with a robust portfolio of approved products for the.
/PRNewswire/ - "Apex files phase 2a Clinical Trial Application ("CTA") with Health Canada and announces Series A financing" Apex is pleased to announce its new.